Wikipedia

Kaposi's sarcoma-associated herpesvirus

(Redirected from HHV-8)

Kaposi's sarcoma-associated herpesvirus (KSHV) is the ninth known human herpesvirus; its formal name according to the International Committee on Taxonomy of Viruses (ICTV) is Human gammaherpesvirus 8, or HHV-8 in short.[1] Like other herpesviruses, its informal names are used interchangeably with its formal ICTV name. This virus causes Kaposi's sarcoma, a cancer commonly occurring in AIDS patients,[2] as well as primary effusion lymphoma,[3] HHV-8-associated multicentric Castleman's disease and KSHV inflammatory cytokine syndrome.[4] It is one of seven currently known human cancer viruses, or oncoviruses.[2] Even after many years since the discovery of KSHV/HHV8, there is no known cure for KSHV associated tumorigenesis.

Human gammaherpesvirus 8
Kaposi's sarcoma
Virus classification Edit this classification
(unranked): Virus
Realm: Duplodnaviria
Kingdom: Heunggongvirae
Phylum: Peploviricota
Class: Herviviricetes
Order: Herpesvirales
Family: Orthoherpesviridae
Genus: Rhadinovirus
Species:
Human gammaherpesvirus 8

History

edit

In 1872, Moritz Kaposi described a blood vessel tumor[5] (originally called "idiopathic multiple pigmented sarcoma of the skin") that has since been eponymously named Kaposi's sarcoma (KS). KS was at first thought to be an uncommon tumor of Jewish and Mediterranean populations until it was later determined to be extremely common throughout sub-Saharan African populations. This led to the first suggestions in the 1950s that this tumor might be caused by a virus. With the onset of the AIDS epidemic in the early 1980s, there was a sudden resurgence of KS affecting AIDS patients, with up to 50% of reported AIDS patients having this tumor—an extraordinary rate of cancer predisposition.[6]

Careful analysis of epidemiologic data by Valerie Beral, Thomas Peterman and Harold Jaffe,[7] led these investigators to propose that KS is caused by an unknown sexually transmitted virus that rarely causes tumors unless the host becomes immunosuppressed, as in AIDS.[citation needed]

 
Micrograph of Kaposi sarcoma. H&E stain.

As early as 1984, scientists reported seeing herpesvirus-like structures in KS tumors examined under electron microscopy. Scientists had been searching for the agent causing KS, and over 20 agents were proposed as the possible cause, including cytomegalovirus and HIV itself. The pathogen was ultimately identified in 1994 by Yuan Chang and Patrick S. Moore, a wife and husband team at Columbia University, through the isolation of DNA fragments from a herpesvirus found in a KS tumor in an AIDS patient.[8][9][10] Chang and Moore used representational difference analysis, or RDA, to find KSHV by comparing KS tumor tissue from an AIDS patient to his own unaffected tissue. The idea behind this experiment was that if a virus causes KS, the genomic DNA in the two samples should be precisely identical except for DNA belonging to the virus. In their initial RDA experiment, they isolated two small DNA fragments that represented less than 1% of the actual viral genome. These fragments were similar (but still distinct from) the known herpevirus sequences, indicating the presence of a new virus. Starting from these fragments, this research team was then able to sequence the entire genome of the virus less than two years later.[citation needed]

The discovery of this herpesvirus sparked considerable controversy and scientific in-fighting until sufficient data had been collected to show that indeed KSHV was the causative agent of Kaposi's sarcoma.[11] The virus is now known to be a widespread infection of people living in sub-Saharan Africa; intermediate levels of infection occur in Mediterranean populations (including Lebanon, Saudi Arabia, Italy, and Greece) and low levels of infection occur in most Northern European and North American populations. Gay and bisexual men are more susceptible to infection (through still unknown routes of sexual transmission) whereas the virus is transmitted through non-sexual routes in developing countries.[citation needed]

Virology

edit

KSHV is a herpesvirus, and is a large double-stranded DNA virus with a protein covering that packages its nucleic acids, called the capsid, which is then surrounded by an amorphous protein layer called the tegument, and finally enclosed in a lipid envelope derived in part from the cell membrane. KSHV has a genome which is approximately 165,000 nucleic acid bases in length. The viral genome consists of a ~145 kilobase-long unique region, encoding all of expressed viral genes, which is flanked by ~20-30 kilobases of terminal repeat sequences.[12] Each terminal repeat unit is 801 bp in length, has 85% G C content and is oriented in a repetitive head-to-tail fashion. KSHV is a rhadinovirus, a Herpes genus remarkable since it has stolen numerous genes from host cells including, in the case of KSHV, genes that encode for complement-binding protein, IL-6, BCL-2, cyclin-D, a G protein-coupled receptor, interferon regulatory factor and Flice inhibitory protein (FLIP), as well as DNA synthesis proteins including dihydrofolate reductase, thymidine kinase, thymidylate synthetase, DNA polymerase and many others. While no other human tumor virus possesses these same genes, other tumor viruses target the same cellular pathways illustrating that at a basic level, all tumor viruses appear to attack the same cellular control pathways, so-called tumor suppressor pathways.[citation needed]

Crucial for the entry of KSHV into cells [13] are the EPH receptor A2,[14] Hrs,[15] TSG101,[16] and a few integrins (whose identity has yet to be confirmed).[17] After infection, the virus enters into lymphocytes via macropinosomes.[citation needed] Once the virus newly infects a cell, the lipid membrane is shed and the virion travels to the nucleus. The viral genome is released where it circularizes into an episome through a poorly understood process that appears to involve homologous recombination of the terminal repeats.[citation needed] The viral episome is chromatinized upon entry into the host cell nucleus.[18]

After entry, the virus typically remains in a latent ("quiet") state. Only a subset of genes that are encoded in the KSHV latency associated region (KLAR) are expressed during latency, including latency-associated nuclear antigen (LANA), vFLIP, vCyclin and 12 microRNAs. Latency is the hallmark of all KSHV-associated etiologies known to date including all KSHV-associated oncogenesis. It has been shown that both protein coding genes such as LANA and noncoding genes (microRNAs) encoded in KLAR are important for KSHV associated tumorigenesis. To study the functions of microRNAs, a detailed protocol of bacmid mutagenesis and a complete set of cell-lines carrying microRNA deletion mutants have been established and are available as a resource to researchers.[19] Additionally, it has been shown that vFLIP and vCyclin interfere with the TGF-β signaling pathway indirectly by inducing the oncogenic host mir17-92 cluster.[20] These observations represents a novel mechanism that may be important for KSHV tumorigenesis and angiogenesis, a hallmark of KS.[citation needed]

During latency, LANA is the only viral protein that is required for viral replication, which is carried out by the host replication machinery. LANA tethers the viral DNA to cellular chromosomes, inhibits p53 and retinoblastoma protein and suppresses viral genes needed for full virus production and assembly ("lytic replication"). Why only a subset of virus genes expressed during latency is not fully understood. But it has been shown that the latency associated gene expression can be explained in part by a characteristic epigenetic state that KSHV episome acquires during latency. LANA plays an important role during latency, regulating both host and virus transcripts and binding to multiple active promoters; it also associates with the host protein hSET1 that creates H3K4me3 marks in chromatin.[21]

Various signals such as inflammation may provoke the virus to enter into lytic replication. The primary viral protein responsible for the switch between latent and lytic replication is known as the ORF50 Replication Transactivation Activator (RTA). When cell signaling conditions activate the generation of RTA, it in turn activates synthesis of a stereotypic cascade of secondary and tertiary viral proteins that ultimately make components of the virus capsid and also the DNA synthesis enzymes required to replicate the virus genome.[22] During lytic replication, it is believed that the virus genome is replicated as a continuous linear molecule off of an episome (so-called rolling circle model). As each unit genome is replicated, it is cut within the terminal repeat region, and then packaged into a virus particle (virion). The virus then becomes enveloped with a lipid membrane as it transits the nucleus and the cytoplasm to exit the cell. Thus, whereas KSHV genome is circular in the nucleus of latently infected cells, it is packaged into infectious viruses as a linear molecule. When the virus enters into lytic replication, thousands of virus particles can be made from a single cell, which usually results in death of the infected cell.[citation needed]

COVID-19 and KSHV

edit

It was discovered in 2020 that infection with the SARS-CoV-2 virus, the virus which causes COVID-19, may induce the lytic reactivation of KSHV in the human body, causing the herpes virus to cease latency and begin the formation of cancerous cells. Further, it was discovered that some medications used to treat the infection with SARS-CoV-2, namely Nafamostat and Azithromycin, ended up promoting the production of mature virions, "... potentially inducing KSHV lytic reactivation."[23]

Pathophysiology

edit

The mechanisms by which the virus is contracted are not well understood. Healthy individuals can be infected with the virus and show no signs or symptoms, due to the immune system's ability to keep the infection in check. Infection is of particular concern to the immunocompromised. Cancer patients receiving chemotherapy, AIDS patients, and organ transplant patients are all at a high risk of showing signs of infection.[citation needed].

Recent advances in sequencing technologies have uncovered that virus is chromatinized during latency. It has also been shown that virus encoded microRNA manipulates and interacts not only with host mRNA but also deregulate host long non-coding RNA (lncRNA).[24] More recently, circularRNAs (circRNAs) are recently discovered in both EBV and KSHV [25][26][27]

Infection with this virus is thought to be lifelong, but a healthy immune system will keep the virus in check. Many people infected with KSHV will never show any symptoms. Kaposi's sarcoma occurs when someone who has been infected with KSHV becomes immunocompromised due to AIDS, medical treatment, or, very rarely, aging.

KSHV is a known causative agent of four diseases:[4][28]

Epidemiology

edit

In the 1970s, the global prevalence rate for HHV-8 was 2 to 10%.[29] The seroprevalence of HHV-8 varies significantly geographically and infection rates in northern European, southeast Asian, and Caribbean countries are between 2-4%,[30] in Mediterranean countries at approximately 10%, and in sub-Saharan African countries at approximately 40%.[31] In South America, infection rates are low in general but are high among Amerindians.[32] Even within individual countries, significant variation can be observed across different regions, with infection rates of about 19.2% in Xinjiang compared to about 9.5% in Hubei, China.[33] Although seroprevalence has been consistently shown to increase with age in a linear manner,[33][34][35][36] countries with high infection rates may see higher seroprevalence in younger age groups.[37] Educational level has shown an inverse correlation with infection rates.[34][35] Individuals infected with HIV-1 or genital warts are generally more likely to be co-infected with HHV-8.[31][33][38]

In countries with low seroprevalence, HHV-8 is primarily limited to AIDS and KS patients.[39] In countries with high seroprevalence, infection is frequent in childhood,[40] indicating a likely mother-to-child transmission by saliva.[41][42] In a Zambian survey, all children with KS had mothers who were positive for HHV-8, whereas not all children whose mothers had KS were HHV-8 positive.[43] In another Zambian survey, 13.8% of children were seropositive for HHV-8 by age 4.[44] Seroprevalence has not been shown to vary significantly because of gender or marital status.[36]

Evolution

edit

The most recent common ancestor of this virus in the Mediterranean, Iran, and Xinjiang, China, has been estimated to have evolved 29,872 years (95% highest probability density 26,851–32,760 years) ago.[45] the most recent common ancestor for viruses isolated in Xinjiang was 2037 years (95% highest probability density 1843–2229 years) ago. Given the historical links between the Mediterranean and Xinjiang during the Roman period it seems likely that this virus was introduced to Xinjiang along the Silk Road. The mutation rate was estimated to be 3.44×10−6 substitutions per site per year (95% highest probability density 2.2×10−6 to 4.71×10−6). However, the global distribution of different genotypes of KSHV and the potential transmission path need further studies.[citation needed]

Typing of isolates is based on the variable K1 membrane protein. Six types are recognised (A–F).[46]

Prevention

edit

Since persons infected with KSHV will asymptomatically give the virus, caution should be used by sex partners in having unprotected sex and activities where saliva might be shared during sexual activity. Prudent advice is to use condoms when needed and avoid deep kissing with partners who may have KSHV infections.

Treatment

edit

Kaposi's sarcoma is usually a localized tumor that can be treated either surgically or through local irradiation. Chemotherapy with drugs such as liposomal anthracyclines or paclitaxel may be used, particularly for invasive disease. Antiviral drugs, such as ganciclovir, that target the replication of herpesviruses such as KSHV have been used to successfully prevent development of Kaposi's sarcoma,[47] although once the tumor develops these drugs are of little or no use. For patients with AIDS-KS, the most effective therapy is highly active antiretroviral therapy to reduce HIV infection.[48] AIDS patients receiving adequate anti-HIV treatment may have up to a 90% reduction in Kaposi's sarcoma occurrence.

Although KSHV affects the host immune system, there is ample chance for clinical intervention to recover this change. One challenge is overexpression inhibitory of target cell repress immune. Under longtime inflammation stimulation, the target cell becomes unable to respond, which leads to an exhausted phenotype. The activation immunotherapies can revive and enhance immune cell function. Comparing to other immunotherapies, therapies targeting the anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) has been a great success. Because of KSHV infection, the monocytes increase the expression of PD-1, which is an inhibitory molecule, and cause immune escape in many tumor types. There is high PD-1 expression in NK cells from KS-HIV patients and cause exhausted phenotype. The anti-PD-1 antibody, (nivolumab or pembrolizumab), demonstrated a significant antitumor effect. Nivolumab is currently an ongoing phase I clinical trial, and Pembrolizumab has shown its function in treatment for HIV and KS patients in phase I and is in a phase II trial for treatment. A thalidomide analog medicine – Pomalidomide was also granted by the FDA in 2011. Pomalidomide was shown to recover the expression of MHC-1, which help cell display intracellular proteins to cytotoxic T cells, and it also can repress the expression of PD-L1 and increase the CD8 T cell killing.[49]

KSHV genes

edit

KSHV encodes for ~90 genes and multiple non-coding RNAs, such as microRNAs.[50] The "ORF" genes are named based on genome position of the homologous genes in the first rhadinovirus described, herpesvirus saimiri. The "K" genes are unique to KSHV, Some KSHV genes have well-characterized functions, while others remain uncharacterized.[citation needed]

ORF2 – dihydrofolate reductase

ORF8 – gB – envelope glycoprotein involved in viral entry

ORF9 – Pol8 – DNA polymerase required for viral DNA replication

ORF10 – regulates RNA export and responses to type I IFNs

ORF16 – vBcl2

ORF18, ORF24, ORF30, ORF31, ORF34, ORF66 – viral transcription factors required for the expression of late genes

ORF21 – vTK – thymidine kinase

ORF22 – gH – envelope glycoprotein involved in viral entry

ORF23 – uncharacterized

ORF25, ORF26 and ORF65 – capsid proteins

ORF33 – involved in viral particle formation

ORF34 – unclear function

ORF35 – unclear function, mutant does not express early viral genes

ORF36 – vPK – viral protein kinase with multiple roles in replication cycle

ORF37 – SOX – dual function protein – DNase activity required for genome packaging and RNase activity regulates host gene expression

ORF38 – involved in viral particle formation

ORF39 – gM – envelope glycoprotein

ORF40 and ORF41 – helicase and primase – DNA replication

ORF42 – uncharacterized

ORF45 – tegument protein, binds and prevents dephosphorylation of p90 ribosomal S6 kinases (RSKs) and ERK for modulate the ERK/RSK MAPK signaling pathway

ORF47 – gL – envelope glycoprotein involved in viral entry

ORF49 – may be required for viral gene expression

ORF50 – RTA, replication and transcription activator – the major transcription factor driving lytic KSHV reactivation

ORF52 – KicGAS – tegument protein required for formation of virions and inhibition of cGAS DNA sensing

ORF53 – gN – envelope glycoprotein

ORF55 – uncharacterized

ORF57 – MTA – regulates RNA stability, export and translation of viral genes

ORF59 – PF–8 – polymerase processivity factor, accessory subunit of viral DNA polymerase

ORF67 and ORF69 – nuclear egress

ORF70 – thymidylate synthase

ORF72 – vCyclin

ORF73 – LANA, latency-associated nuclear antigen– tethers genome to chromosome during latency, also regulates host gene expression. A cytoplasmic form of LANA may inhibit activation of immune responses.

ORF74 – vGPCR

ORF75 – FGARAT

PAN, polyadenylated nuclear RNA – non–coding linear and circular RNAs

miRNAs (mirKs) – viral microRNAs expressed during latency to regulate proliferation and cell death

K1 – involved in oncogenesis

K2 – Interleukin 6 homolog, Q2HRC7

K3 and K5 – ubiquitin E3 ligases – regulates antigen presentation

K4 – vCCL2 – chemokine

K4.1 – vCCL3 – chemokine

K8 – transcriptional repressor – modulates chromatin

K8.1 – envelope glycoprotein

K9 – vIRF1, viral interferon regulatory factor 1

K10 – vIRF4. A circular RNA (circRNA) is also generated from this locus.

K10.5 – vIRF3 (initially designated LANA2), is expressed during latency in PEL cell lines, but is also a bona fide lytic factor, like all of the vIRFs.[51]

K11 – vIRF2

K12 – kaposin

K13 – vFLIP

See also

edit

References

edit
  1. ^ "ICTV Master Species List 2018b.v2". International Committee on Taxonomy of Viruses. Archived from the original on March 30, 2019. Retrieved 13 June 2019.
  2. ^ a b Boshoff, C.; Weiss, R. (2002). "Aids-related malignancies". Nature Reviews Cancer. 2 (5): 373–382. doi:10.1038/nrc797. PMID 12044013. S2CID 13513517.
  3. ^ Cesarman, E.; Chang, Y.; Moore, P. S.; Said, J. W.; Knowles, D. M. (1995). "Kaposi's Sarcoma–Associated Herpesvirus-Like DNA Sequences in AIDS-Related Body-Cavity–Based Lymphomas". New England Journal of Medicine. 332 (18): 1186–1191. doi:10.1056/NEJM199505043321802. PMID 7700311.
  4. ^ a b Goncalves, Priscila H.; Ziegelbauer, Joseph; Uldrick, Thomas S.; Yarchoan, Robert (2017). "Kaposi sarcoma herpesvirus-associated cancers and related diseases". Curr Opin HIV AIDS. 12 (1): 47–56. doi:10.1097/COH.0000000000000330. PMC 6311702. PMID 27662501.
  5. ^ Kaposi, M (1872). "Idiopathisches multiples Pigmentsarkom der Haut". Archiv für Dermatologie und Syphilis. 4 (2): 265–273. doi:10.1007/BF01830024. S2CID 31438763.
    Translated in Kaposi, M (2008). "Idiopathic multiple pigmented sarcoma of the skin". CA: A Cancer Journal for Clinicians. 32 (6): 342–347. doi:10.3322/canjclin.32.6.342. S2CID 72037330.
  6. ^ La Ferla, L.; Pinzone, M. R.; Pellicanò, G. F.; Nunnari, G. (2016-04-01). "Kaposi's sarcoma in HIV-infected patients: a review of the literature". Infectious Diseases and Tropical Medicine. p. 2. Retrieved 2023-02-21.
  7. ^ Beral V, Peterman TA, Berkelman RL, Jaffe HW (1990). "Kaposi's sarcoma among persons with AIDS: a sexually transmitted infection?". Lancet (Submitted manuscript). 335 (8682): 123–8. doi:10.1016/0140-6736(90)95001-L. PMID 1967430. S2CID 35639169.
  8. ^ Chang, Y.; Cesarman, E.; Pessin, M. S.; Lee, F.; Culpepper, J.; Knowles, D. M.; Moore, P. S. (1994). "Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma". Science. 266 (5192): 1865–1869. Bibcode:1994Sci...266.1865C. doi:10.1126/science.7997879. PMID 7997879.
  9. ^ Moore PS, Chang Y (May 1995). "Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma in patients with and without HIV infection". The New England Journal of Medicine. 332 (18): 1181–5. doi:10.1056/NEJM199505043321801. PMID 7700310. S2CID 13465834.
  10. ^ Antman, K.; Chang, Y. (2000). "Kaposi's Sarcoma". New England Journal of Medicine. 342 (14): 1027–1038. doi:10.1056/NEJM200004063421407. PMID 10749966.
  11. ^ Boshoff C, Weiss RA (May 2000). "Addressing Controversies Over Kaposi's Sarcoma". Journal of the National Cancer Institute. 92 (9): 677–679. doi:10.1093/jnci/92.9.677. PMID 10793096.
  12. ^ Russo JJ, Bohenzky RA, Chien MC, et al. (December 1996). "Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8)". Proceedings of the National Academy of Sciences of the United States of America. 93 (25): 14862–7. Bibcode:1996PNAS...9314862R. doi:10.1073/pnas.93.25.14862. PMC 26227. PMID 8962146.
  13. ^ Kumar, Binod; Chandran, Bala (November 14, 2016). "KSHV Entry and Trafficking in Target Cells-Hijacking of Cell Signal Pathways, Actin and Membrane Dynamics". Viruses. 8 (11): 305. doi:10.3390/v8110305. ISSN 1999-4915. PMC 5127019. PMID 27854239.
  14. ^ Neipel F, Fleckenstein B, Hahn A, et al. (June 2012). "The ephrin receptor tyrosine kinase A2 is a cellular receptor for Kaposi's sarcoma-associated herpesvirus". Nature Medicine. 18 (6): 961–968. doi:10.1038/nm.2805. PMC 3645317. PMID 22635007.
  15. ^ Veettil, Mohanan Valiya; Kumar, Binod; Ansari, Mairaj Ahmed; Dutta, Dipanjan; Iqbal, Jawed; Gjyshi, Olsi; Bottero, Virginie; Chandran, Bala (April 2016). "ESCRT-0 Component Hrs Promotes Macropinocytosis of Kaposi's Sarcoma-Associated Herpesvirus in Human Dermal Microvascular Endothelial Cells". Journal of Virology. 90 (8): 3860–3872. doi:10.1128/JVI.02704-15. ISSN 1098-5514. PMC 4810545. PMID 26819309.
  16. ^ Kumar, Binod; Dutta, Dipanjan; Iqbal, Jawed; Ansari, Mairaj Ahmed; Roy, Arunava; Chikoti, Leela; Pisano, Gina; Veettil, Mohanan Valiya; Chandran, Bala (October 2016). "ESCRT-I Protein Tsg101 Plays a Role in the Post-macropinocytic Trafficking and Infection of Endothelial Cells by Kaposi's Sarcoma-Associated Herpesvirus". PLOS Pathogens. 12 (10): e1005960. doi:10.1371/journal.ppat.1005960. ISSN 1553-7374. PMC 5072609. PMID 27764233.
  17. ^ Campadelli-Fiume G, Collins-McMillen D, et al. (July 2016). "Integrins as Herpersvirus Receptors and Mediators of the Host Signalosome". Annual Review of Virology. 3 (1): 215–236. doi:10.1146/annurev-virology-110615-035618. hdl:11585/593080. PMID 27501260.
  18. ^ Purushothaman, et al. (February 2016). "KSHV Genome Replication and Maintenance". Frontiers in Microbiology. 7: 54. doi:10.3389/fmicb.2016.00054. PMC 4740845. PMID 26870016.
  19. ^ Jain, Vaibhav; Plaisance-Bonstaff, Karlie; Sangani, Rajnikumar; Lanier, Curtis; Dolce, Alexander; Hu, Jianhong; Brulois, Kevin; Haecker, Irina; Turner, Peter; Renne, Rolf; Krueger, Brian (19 February 2016). "A Toolbox for Herpesvirus miRNA Research: Construction of a Complete Set of KSHV miRNA Deletion Mutants". Viruses. 8 (2): 54. doi:10.3390/v8020054. ISSN 1999-4915. PMC 4776209. PMID 26907327.
  20. ^ Choi, HS; Jain, V; Krueger, B; Marshall, V; Kim, CH; Shisler, JL; Whitby, D; Renne, R (2015). "Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Induces the Oncogenic miR-17-92 Cluster and Down-Regulates TGF-β Signaling". PLOS Pathogens. 11 (11): e1005255. doi:10.1371/journal.ppat.1005255. PMC 4636184. PMID 26545119.
  21. ^ Hu, J; Yang, Y; Turner, PC; Jain, V; McIntyre, LM; Renne, R (July 2014). "LANA binds to multiple active viral and cellular promoters and associates with the H3K4methyltransferase hSET1 complex". PLOS Pathogens. 10 (7): e1004240. doi:10.1371/journal.ppat.1004240. PMC 4102568. PMID 25033463.
  22. ^ Bu W, Palmeri D, Krishnan R, et al. (November 2008). "Identification of Direct Transcriptional Targets of the Kaposi's Sarcoma-Associated Herpesvirus Rta Lytic Switch Protein by Conditional Nuclear Localization". Journal of Virology. 82 (21): 10709–23. doi:10.1128/JVI.01012-08. PMC 2573185. PMID 18715905.
  23. ^ Angela Betsaida B. Laguipo (6 October 2020). "SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus". News Medical Life Sciences.
  24. ^ Sethuraman, S; Gay, LA; Jain, V; Haecker, I; Renne, R (July 2017). "microRNA dependent and independent deregulation of long non-coding RNAs by an oncogenic herpesvirus". PLOS Pathogens. 13 (7): e1006508. doi:10.1371/journal.ppat.1006508. PMC 5531683. PMID 28715488.
  25. ^ Toptan, T; Abere, B; Nalesnik, MA; Swerdlow, SH; Ranganathan, S; Lee, N; Shair, KH; Moore, PS; Chang, Y (11 September 2018). "Circular DNA tumor viruses make circular RNAs". Proceedings of the National Academy of Sciences of the United States of America. 115 (37): E8737–E8745. Bibcode:2018PNAS..115E8737T. doi:10.1073/pnas.1811728115. PMC 6140489. PMID 30150410.
  26. ^ Tagawa, T; Gao, S; Koparde, VN; Gonzalez, M; Spouge, JL; Serquiña, AP; Lurain, K; Ramaswami, R; Uldrick, TS; Yarchoan, R; Ziegelbauer, JM (11 December 2018). "Discovery of Kaposi's sarcoma herpesvirus-encoded circular RNAs and a human antiviral circular RNA". Proceedings of the National Academy of Sciences of the United States of America. 115 (50): 12805–12810. Bibcode:2018PNAS..11512805T. doi:10.1073/pnas.1816183115. PMC 6294913. PMID 30455306.
  27. ^ Ungerleider, NA; Jain, V; Wang, Y; Maness, NJ; Blair, RV; Alvarez, X; Midkiff, C; Kolson, D; Bai, S; Roberts, C; Moss, WN; Wang, X; Serfecz, J; Seddon, M; Lehman, T; Ma, T; Dong, Y; Renne, R; Tibbetts, SA; Flemington, EK (15 March 2019). "Comparative Analysis of Gammaherpesvirus Circular RNA Repertoires: Conserved and Unique Viral Circular RNAs". Journal of Virology. 93 (6). doi:10.1128/JVI.01952-18. PMC 6401440. PMID 30567979.
  28. ^ Chen BJ, Chuang SS (March 2020). "Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches". Advances in Anatomic Pathology. 27 (2): 61–74. doi:10.1097/PAP.0000000000000253. PMID 31725418.
  29. ^ Gallo, Robert C. (1998-12-04). "The Enigmas of Kaposi's Sarcoma". Science. 282 (5395): 1837–1839. doi:10.1126/science.282.5395.1837. ISSN 0036-8075. PMID 9874635. S2CID 29362584.
  30. ^ Zhang, Tiejun; Wang, Linding (2016). "Epidemiology of Kaposi's sarcoma-associated Herpesvirus in Asia: Challenges and Opportunities". Journal of Medical Virology. 89 (4): 563–570. doi:10.1002/jmv.24662. ISSN 0146-6615. PMID 27531516. S2CID 1145299.
  31. ^ a b Chatlynne, L. G.; Ablashi, D. V. (1999). "Seroepidemiology of Kaposi's sarcoma-associated herpesvirus (KSHV)". Seminars in Cancer Biology. 9 (3): 175–85. doi:10.1006/scbi.1998.0089. PMID 10343069.
  32. ^ Mohanna, S; Maco, V; Bravo, F; Gotuzzo, E (2005). "Epidemiology and clinical characteristics of classic Kaposi's sarcoma, seroprevalence, and variants of human herpesvirus 8 in South America: A critical review of an old disease". International Journal of Infectious Diseases. 9 (5): 239–50. doi:10.1016/j.ijid.2005.02.004. PMID 16098630.
  33. ^ a b c Fu, B; Sun, F; Li, B; Yang, L; Zeng, Y; Sun, X; Xu, F; Rayner, S; Guadalupe, M; Gao, S. J.; Wang, L (2009). "Seroprevalence of Kaposi's sarcoma-associated herpesvirus and risk factors in Xinjiang, China". Journal of Medical Virology. 81 (8): 1422–31. doi:10.1002/jmv.21550. PMC 2755560. PMID 19551832.
  34. ^ a b Pelser, C; Vitale, F; Whitby, D; Graubard, B. I.; Messina, A; Gafà, L; Brown, E. E.; Anderson, L. A.; Romano, N; Lauria, C; Goedert, J. J. (2009). "Socio-economic and other correlates of Kaposi sarcoma-associated herpesvirus seroprevalence among older adults in Sicily". Journal of Medical Virology. 81 (11): 1938–44. doi:10.1002/jmv.21589. PMC 2784645. PMID 19777527.
  35. ^ a b Wang, H; Liu, J; Dilimulati; Li, L; Ren, Z; Wen, H; Wang, X (2011). "Seroprevalence and risk factors of Kaposi's sarcoma-associated herpesvirus infection among the general Uygur population from south and north region of Xinjiang, China". Virology Journal. 8: 539. doi:10.1186/1743-422X-8-539. PMC 3266657. PMID 22168313.
  36. ^ a b Olsen, S. J.; Chang, Y; Moore, P. S.; Biggar, R. J.; Melbye, M (1998). "Increasing Kaposi's sarcoma-associated herpesvirus seroprevalence with age in a highly Kaposi's sarcoma endemic region, Zambia in 1985". AIDS. 12 (14): 1921–5. doi:10.1097/00002030-199814000-00024. PMID 9792393. S2CID 1734745.
  37. ^ Wawer, M. J.; Eng, S. M.; Serwadda, D; Sewankambo, N. K.; Kiwanuka, N; Li, C; Gray, R. H. (2001). "Prevalence of Kaposi sarcoma-associated herpesvirus compared with selected sexually transmitted diseases in adolescents and young adults in rural Rakai District, Uganda". Sexually Transmitted Diseases. 28 (2): 77–81. doi:10.1097/00007435-200102000-00003. PMID 11234789. S2CID 7592869.
  38. ^ Klaskala, W; Brayfield, B. P.; Kankasa, C; Bhat, G; West, J. T.; Mitchell, C. D.; Wood, C (2005). "Epidemiological characteristics of human herpesvirus-8 infection in a large population of antenatal women in Zambia". Journal of Medical Virology. 75 (1): 93–100. doi:10.1002/jmv.20242. PMID 15543582. S2CID 9051177.
  39. ^ Kourí, V; Eng, S. M.; Rodríguez, M. E.; Resik, S; Orraca, O; Moore, P. S.; Chang, Y (2004). "Seroprevalence of Kaposi's sarcoma-associated herpesvirus in various populations in Cuba". Revista Panamericana de Salud Pública. 15 (5): 320–5. doi:10.1590/s1020-49892004000500006. PMID 15231079.
  40. ^ Schulz, T. F. (2000). "Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8): Epidemiology and pathogenesis". The Journal of Antimicrobial Chemotherapy. 45 Suppl T3 (95004): 15–27. doi:10.1093/jac/45.suppl_4.15. PMID 10855768.
  41. ^ Mesri, Enrique A.; Cesarman, Ethel; Boshoff, Chris (October 2010). "Kaposi's sarcoma herpesvirus/ Human herpesvirus-8 (KSHV/HHV8), and the oncogenesis of Kaposi's sarcoma". Nature Reviews. Cancer. 10 (10): 707–19. doi:10.1038/nrc2888. PMC 4721662. PMID 20865011.
  42. ^ Brayfield, B. P.; Phiri, S; Kankasa, C; Muyanga, J; Mantina, H; Kwenda, G; West, J. T.; Bhat, G; Marx, D. B.; Klaskala, W; Mitchell, C. D.; Wood, C (2003). "Postnatal human herpesvirus 8 and human immunodeficiency virus type 1 infection in mothers and infants from Zambia". The Journal of Infectious Diseases. 187 (4): 559–68. doi:10.1086/367985. PMID 12599072.
  43. ^ He, J; Bhat, G; Kankasa, C; Chintu, C; Mitchell, C; Duan, W; Wood, C (1998). "Seroprevalence of human herpesvirus 8 among Zambian women of childbearing age without Kaposi's sarcoma (KS) and mother-child pairs with KS". The Journal of Infectious Diseases. 178 (6): 1787–90. doi:10.1086/314512. PMID 9815235.
  44. ^ Minhas, V; Crabtree, K. L.; Chao, A; m'Soka, T. J.; Kankasa, C; Bulterys, M; Mitchell, C. D.; Wood, C (2008). "Early childhood infection by human herpesvirus 8 in Zambia and the role of human immunodeficiency virus type 1 coinfection in a highly endemic area". American Journal of Epidemiology. 168 (3): 311–20. doi:10.1093/aje/kwn125. PMC 2727264. PMID 18515794.
  45. ^ Liu Z, Fang Q, Zuo J, Minhas V, Wood C, He N, Zhang T (2017) Was Kaposi's sarcoma-associated herpesvirus introduced into China via the ancient Silk Road? An evolutionary perspective. Arch Virol
  46. ^ Jary A, Leducq V, Desire N, Petit H, Palich R, Joly V, Canestri A, Gothland A, Lambert-Niclot S, Surgers L, Amiel C, Descamps D, Spano JP, Katlama C, Calvez V, Marcelin AG (2020) New Kaposi's sarcoma-associated herpesvirus variant in men who have sex with men associated with severe pathologies. J Infect Dis
  47. ^ Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA (April 1999). "Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group". The New England Journal of Medicine. 340 (14): 1063–70. doi:10.1056/NEJM199904083401402. PMID 10194235.
  48. ^ Yarchoan, R.; Tosato, G.; Little, R. F. (2005). "Therapy insight: AIDS-related malignancies – the influence of antiviral therapy on pathogenesis and management". Nature Clinical Practice Oncology. 2 (8): 406–415, quiz 415. doi:10.1038/ncponc0253. PMID 16130937. S2CID 23476060.
  49. ^ Broussard, Grant; Damania, Blossom (2020-02-07). "KSHV: Immune Modulation and Immunotherapy". Frontiers in Immunology. 10: 3084. doi:10.3389/fimmu.2019.03084. ISSN 1664-3224. PMC 7025529. PMID 32117196.
  50. ^ Samols MA, Hu J, Skalsky RL, Renne R (Jul 2005). "Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcoma-associated herpesvirus". Journal of Virology. 79 (14): 9301–5. doi:10.1128/JVI.79.14.9301-9305.2005. PMC 1168752. PMID 15994824.
  51. ^ Golas, G.; Jang, S. J.; Naik, N. G.; Alonso, J. D.; Papp, B.; Toth, Z. (2020). "Comparative analysis of the viral interferon regulatory factors of KSHV for their requisite for virus production and inhibition of the type I interferon pathway". Virology. 541: 160–173. doi:10.1016/j.virol.2019.12.011. PMC 7024068. PMID 32056714.

Further reading

edit
edit
 
Wikimedia Commons has media related to Human herpesvirus 8.
 
Wikispecies has information related to Kaposi's sarcoma-associated herpesvirus.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Kaposi's_sarcoma-associated_herpesvirus&oldid=1245734446"